Physician profile
Ester R Hare
NPI 1538144795
$1,318.19
in general payments reported to CMS, 2019-2025
18 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $11.03 · 2021: $13.36 · 2022: $116 · 2023: $211 · 2024: $399 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $426.17 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.52 | 2023-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $128.42 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $125.02 | 2019-2024 | Zepbound, Jardiance |
| Pfizer INC. | $96.06 | 2019-2024 | |
| Genzyme Corporation | $70.85 | 2025 | |
| Merck Sharp & Dohme LLC | $38.03 | 2019 | |
| Dexcom, INC. | $36.36 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $29.91 | 2019-2023 | Infinity |
| Sanofi-Aventis U.S. LLC | $28.67 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.46 | 2025 | Zoryve |
| Exact Sciences Corporation | $22.09 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $18.25 | 2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $16.75 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $16.73 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.28 | 2019 | |
| Amgen INC. | $15.26 | 2025 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ester Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.